Lupin Limited Stock Price Today (NSE: LUPIN)

Lupin Limited

2175.5056.50 (2.53%)
Market Closed

Fundamental Score

...

Lupin Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Lupin Limited share price today is 2175.50, down 2.53% on NSE/BSE as of 25 August 2026. Lupin Limited (LUPIN) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of 1.14L (Cr). The 52-week high for LUPIN share price is 2526.90 and the 52-week low is 1875.00. At a P/E ratio of 20.62x, LUPIN is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 26.90% and a debt-to-equity ratio of 0.26.

Lupin Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
2523.70
Low
2175.50
Volume
11.9L
Change
-9.95%

Lupin Limited share price chart: -9.95% return over the past month. 52-week high ₹2526.90, 52-week low ₹1875.00.

Lupin Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
2182.602189.902158.102175.505.45L (Cr)
2255.002255.002220.502232.006.94L (Cr)
2255.002263.102230.102235.005.91L (Cr)
2268.002278.002250.302250.305.83L (Cr)
2286.602287.802249.502281.008.61L (Cr)
2285.002288.202258.602278.9013.04L (Cr)
2360.002362.802235.002300.0037.47L (Cr)
2410.002410.002346.002363.5020.46L (Cr)
2397.002427.702382.602385.0011.85L (Cr)
2410.002410.002357.502388.0014.95L (Cr)

Lupin Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
2435.002440.002158.102175.50-10.66%
2428.002526.902340.002415.00-0.54%
2285.402440.802219.802419.00+5.85%
2320.002494.002210.602267.70-2.25%
2346.002381.002232.802305.20-1.74%
2275.602377.602241.602313.90+1.68%
2135.302336.302078.202301.90+7.80%
2114.002226.302073.602152.80+1.84%
2094.902146.902036.702109.50+0.70%
1967.002091.401944.102082.20+5.86%
1917.402006.101900.001963.50+2.40%
1887.102062.801875.001911.30+1.28%

Returns & Performance

Excellent

Return on Equity (ROE)

26.90%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

31.80%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

17.67%

Average operating profit margin over 5 years

Dividend Yield

0.72%

Annual dividend as % of current share price

Lupin Limited Valuation Check

Excellent

Price to Earnings (P/E)

20.62x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.

Shareholding Pattern

Excellent

Promoter Holding

46.90%

% shares held by company founders/management

Excellent

FII Holding

21.70%

% shares held by foreign institutional investors

Excellent

DII Holding

25.32%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Average

Profit Growth (Quarterly YoY)

16.08%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

32.04%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

13.02%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

33.93%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

34.39%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.26x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

16.82x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

9.39K (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Lupin Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of LUPIN across key market metrics for learning purposes.

Positive Indicators

14 factors identified

Strong Return on Equity (26.90%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (31.80%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (17.67%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 20.62 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (32.04%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (13.02% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (33.93% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (34.39% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.26)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (16.82x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 1.90)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Strong Cash Generation (₹9387.60 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Strong Institutional Confidence (FII+DII: 47.02%)

Observation: Significant professional investor participation.

Analysis: High institutional holding often signals thorough due diligence.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

1 factors identified

High Price-to-Book Ratio (5.08x)

Observation: Trading at significant premium to book value.

Analysis: High P/B ratios may indicate overvaluation relative to asset base.

Lupin Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Lupin Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
83.4/100
2176
₹113976.53
20.6
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
66.4/100
1875
₹468821.49
38.8
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
8588
₹193163.97
66.0
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4971
₹169902.02
77.9
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
40.2/100
1431
₹116131.81
34.5
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
74.1/100
1116
₹115375.77
25.6
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
61.5/100
2380
₹105053.91
51.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
0.04%
41/100
1179
₹102660.46
31.9
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
24.6/100
1645
₹90035.87
24.3
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
34.1/100
1814
₹84016.75
76.8
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
7.19%
Good
0.13%
30.2/100
418
₹70826.50
143.0
Average
1.39%
Poor
3.06%
Poor
0.4
Excellent
-12.23%
Poor
18.96%
Excellent
0.12%

Lupin Limited PE Ratio History

Historical price-to-earnings ratio for LUPIN — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202571.69₹2109.5029.4x
FY 202441.87₹2355.7056.3x
FY 20239.41₹1322.95140.6x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Lupin Limited Dividend History

Annual cash dividends paid by LUPIN — dividend yield 0.72%

Financial YearDividends Paid (₹ Cr)
FY 2025365.31 Cr
FY 2024182.80 Cr
FY 2023182.50 Cr
FY 2022295.09 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Lupin Limited Quarterly Performance

Latest quarterly metrics for LUPIN — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

32.04%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

16.08%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

13.02%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

34.39%

Compounded annual net profit growth over 5 years

Lupin Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for LUPIN — calculated from daily price history

23RSI 14
Oversold — RSI 23

Selling pressure is heavy — potential reversal zone.

SMA 50
2375
▼ Price below SMA 50 — Short-term bearish
SMA 200
2237
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
1019K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Lupin Limited Financial Statements

Annual income statement, balance sheet and cash flow for Lupin Limited (LUPIN) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Lupin Limited

Loading latest quarterly results...

About LUPIN (Lupin Limited)

Lupin Ltd is a global pharmaceutical powerhouse, deeply rooted in innovation and driven by a commitment to enhancing healthcare accessibility worldwide. From its origins as a manuf...acturer of tuberculosis drugs, the company has broadened its scope considerably, now encompassing a diverse portfolio that spans complex generics, branded formulations, biosimilars, and active pharmaceutical ingredients (APIs). Lupin distinguishes itself through its intensive research and development efforts, focusing on creating novel therapeutic solutions and improving existing treatments across key therapeutic areas. The company's sophisticated manufacturing infrastructure, strategically located across the globe, ensures consistent quality and efficient production to meet the demands of a global market. With a strong emphasis on patient-centricity, Lupin continues to forge partnerships and invest in cutting-edge technologies to address unmet medical needs. Lupin's robust presence in the global pharmaceutical arena is underscored by its strategic market penetration. The company has cultivated significant operations in major markets, including North America, India, and Europe, while also strategically expanding into emerging economies. This geographical diversification reduces risk and provides access to a broader patient base. Lupin's commercial strategy emphasizes the delivery of high-value products and services that improve patient outcomes. By maintaining strong relationships with healthcare professionals, payers, and other stakeholders, Lupin ensures its products are readily available and appropriately utilized. This comprehensive approach contributes to the company's sustained growth and enduring reputation in the industry. The strength of Lupin lies not only in its tangible assets but also in its unwavering commitment to sustainability and ethical business practices. The company places a high priority on environmental stewardship, actively implementing initiatives to minimize its carbon footprint and promote responsible resource management. Lupin's ethical framework is deeply ingrained in its culture, fostering a responsible and transparent work environment. This commitment to corporate social responsibility extends to the communities in which it operates, as Lupin actively supports healthcare programs and initiatives that improve the quality of life for underserved populations. By integrating sustainability and ethical conduct into its core operations, Lupin ensures its long-term success while making a positive impact on the world.

Company Details

Symbol:LUPIN
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Ms. Vinita D. Gupta
CEO & Executive Director
Mr. Ramesh Swaminathan
Executive Director, Global CFO, CRO & Head of API Plus SBU and IT
Mr. Nilesh Deshbandhu Gupta
MD & Executive Director

Corporate Events

Upcoming
Earnings Date
Recent
Ex-Dividend Date

LUPIN Share Price: Frequently Asked Questions

What is the current share price of Lupin Limited?

Lupin Limited (LUPIN) trades at ₹2175.50 on NSE and BSE. Market cap ₹1.14L (Cr). Educational data only.

What is the P/E ratio of Lupin Limited?

Lupin Limited has a P/E of 20.62x vs industry average 34.89x.

What is the Bull Run score for Lupin Limited?

Lupin Limited has a Bull Run score of 83.4/100 based on 25+ financial parameters.

Does Lupin Limited pay dividends?

Lupin Limited has a dividend yield of 0.72%. Past dividends don't guarantee future payments.

What is the ROE of Lupin Limited?

Lupin Limited has ROE of 26.90%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Lupin Limited?

Lupin Limited has debt-to-equity of 0.26.

Is Lupin Limited a good investment?

Bull Run gives Lupin Limited a score of 83.4/100. This is not investment advice — consult a SEBI-registered advisor.